echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer's innovative rare disease drug Vinda All Approved in China

    Pfizer's innovative rare disease drug Vinda All Approved in China

    • Last Update: 2020-02-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    February 12, 2020 / AP / -- Pfizer announced today that the world's first oral preparation of transthyroxine protein stabilizer, Viagra (meglumine chlorobenzoate soft capsule, vyndaqel, 20mg), was approved by China's National Drug Administration on February 5 to treat adult patients with stage I symptoms of transthyroxine amyloidosis polyneuropathy (attr-pn), so as to delay its use Peripheral nerve function damage Andreas PENK, President of Pfizer biopharmaceutical group in China, said: "Pfizer has always been aiming at" bringing breakthrough innovation for patients to change their lives " The approval of new rare disease drug Vader all in China will fill the gap of no effective drugs in the field of treatment of adult patients with ptr-pn stage I symptoms And actively assist clinicians to bring effective treatment programs for patients with such rare diseases " Attr-pn is a rare and fatal neurodegenerative disease Attr-pn is a rare and fatal neurodegenerative disease The pathogenesis of attr-pn is the abnormal folding of monomers caused by the instability of TTR tetramer, which forms the deposition of amyloid The disease is a multi-system disease, mainly manifested as symmetrical nerve dysfunction from distal to proximal limb, involving motor, sensory and autonomic nerves, as well as damage to heart, kidney, eye and other organs Attr-pn is an adult patient onset, about 10 years after the onset of the disease, gradually progressing to the end [1] At present, the disease has been reported successively in neurology, ophthalmology and cardiology in different regions of China [2] Because the clinical characteristics of attr-pn are easy to be confused with other common clinical diseases, and the rare cases make clinicians lack of understanding of it, and the chance of obtaining pathological and genetic diagnosis is limited, leading to the delay of diagnosis of the disease Pfizer's innovative drug to assist the treatment of Chinese attr-pn patients before the emergence of Vader, there was no internationally approved drug to treat attr-pn, the available treatment scheme was only symptomatic treatment, and the prognosis of patients was not ideal Vader has filled in this gap and improved patients' confidence in disease treatment Andreas PENK, President of Pfizer biopharmaceutical group in China, said: "Pfizer is willing to continue to expand and develop in the field of rare diseases in China to meet the unmet needs of more Chinese patients The approval of Vader will provide a new treatment scheme for these attr-pn patients who suffer from rare fatal diseases but have no approved drugs to be treated In the future, Pfizer will continue to introduce innovative drugs into China, so that more patients with rare diseases can get better treatment " Vader was first approved in the European Union in 2011 for the treatment of ttr-pn in adult patients with early symptomatic polyneuropathy to delay peripheral nerve injury At present, Vader has been approved to treat attr-pn in more than 45 countries and regions, including the United Kingdom, Germany, France, Japan, South Korea, Brazil, Mexico, Argentina and Russia Reference: [1] Coehlotal "physician's Guide to ttramyloidosis" [2] Journal of community medicine, Vol.15, No.10, Vol.15, Vol.10, Vol.15, No.10, Vol.15, Vol.10, Vol.15, Vol.10, Vol.15, Vol.10, Vol.10, Vol.15, Vol.10, Vol.15, Vol.10, Vol.15, Vol.10, Vol.10, No.10, Vol.15, Vol.10, No.10, Vol.10, No.10, No.10, No.10, No.10, No.10, No.10, No.10, No.10 Vader was first approved in the European Union in 2011 for the treatment of ttr-pn in adult patients with early symptomatic polyneuropathy to delay peripheral nerve injury Attr-pn is a neurodegenerative disease of amyloidosis, which can cause sensory loss, pain and weakness of lower limbs, and damage of autonomic nervous system At present, Vader has been approved to treat attr-pn in more than 45 countries and regions around the world, such as the United Kingdom, Germany, France, Japan, South Korea, Brazil, Mexico, Argentina and Russia About Pfizer: bringing breakthrough innovation to patients to change their lives in Pfizer, we are committed to using science and our global resources to provide treatments that can extend and significantly improve human life In the exploration, development and production of medical and health products (including innovative drugs and vaccines), we have established quality, safety and value standards Every day, Pfizer employees in developed and emerging markets are committed to promoting health and prevention and treatment programs that can cope with the most difficult diseases of our time Pfizer also works with healthcare professionals, governments and communities around the world to support access to more reliable and affordable healthcare services for people around the world This is consistent with Pfizer's responsibilities as a global innovative biopharmaceutical company For more than 170 years, Pfizer has been striving to provide better and better services for people Source: Pfizer 37
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.